HDL and LDL Were Never Really 'Good' and 'Bad' — Cardiologists Have Moved On

If you've ever had a cholesterol panel done, you've almost certainly been handed a version of the same story: HDL is the good kind, LDL is the bad kind, keep the first one high and the second one low. It's clean, it's memorable, and it fits neatly on a patient handout.

It's also a significant oversimplification — one that cardiologists and lipid researchers have been quietly walking back for years while the public messaging largely stayed put.

How the Good/Bad Framework Got Built

The HDL/LDL distinction became mainstream in the 1980s and 1990s, following landmark research — particularly the Framingham Heart Study — that identified correlations between elevated LDL cholesterol and cardiovascular disease risk. The research was solid. The communication of it was where things got flattened.

Medical messaging has a consistent challenge: simplifying complex biological systems for patients who need actionable information. "Lower your LDL, raise your HDL" is clear guidance that patients can understand and that physicians can deliver in a short appointment. The problem is that the biology underneath it is considerably more complicated, and the simplified version ended up driving both patient expectations and, in some cases, treatment decisions that the research didn't fully support.

The "good cholesterol" label for HDL, in particular, turned out to be more of a correlation than a mechanism.

What Cholesterol Is Actually Doing

First, a clarification that often surprises people: cholesterol itself is not a villain. Your body produces it continuously because it needs it. Cholesterol is a structural component of every cell membrane in your body. It's a precursor to hormones including estrogen, testosterone, and cortisol. It's essential for producing vitamin D and bile acids that help you digest fat. Your liver manufactures it on a daily basis regardless of what you eat, because the demand is constant.

HDL and LDL aren't actually types of cholesterol — they're lipoproteins, meaning they're the protein-and-fat packages that carry cholesterol through your bloodstream. LDL delivers cholesterol to cells throughout the body. HDL carries cholesterol back to the liver for processing. Both functions are necessary.

The cardiovascular risk associated with LDL comes from a specific scenario: when LDL particles accumulate in arterial walls and contribute to plaque formation. But — and this is where the "bad cholesterol" label breaks down — not all LDL behaves the same way.

The Particle Problem

One of the most significant advances in lipid research over the past two decades involves particle size and density. LDL comes in different varieties. Small, dense LDL particles are considerably more likely to penetrate arterial walls and contribute to atherosclerosis than large, buoyant LDL particles. Two patients with identical LDL numbers on a standard cholesterol panel can have very different cardiovascular risk profiles depending on which type of LDL predominates.

Standard lipid panels — the ones most Americans get at annual physicals — don't measure this. They report total LDL cholesterol, which lumps all particle types together.

The HDL story got complicated in a different way. For years, researchers assumed that because high HDL correlated with lower heart disease risk in population studies, raising HDL pharmacologically would reduce that risk. Several drug trials were designed around this premise. They failed — sometimes dramatically. Drugs that successfully raised HDL levels didn't reduce cardiovascular events the way the hypothesis predicted.

That finding forced a rethink. HDL's protective association in population data may reflect general metabolic health rather than a direct causal mechanism. "High HDL" might be a marker of a healthy system, not a lever you can pull independently.

What Doctors Are Actually Looking At Now

Contemporary cardiovascular risk assessment has moved well beyond the basic HDL/LDL split. Here's what increasingly matters in clinical practice:

Triglycerides. These blood fats are a significant part of the cardiovascular risk picture, particularly in combination with other markers. High triglycerides alongside low HDL is a pattern associated with insulin resistance and metabolic syndrome — a combination that carries substantial risk even when LDL looks normal.

ApoB. Apolipoprotein B is a protein found on LDL, VLDL, and other atherogenic particles. Each of those particles carries exactly one ApoB molecule, so measuring ApoB gives a direct count of the total number of potentially harmful particles in circulation — something a standard LDL measurement doesn't capture. Many cardiologists now consider ApoB a more accurate risk marker than LDL cholesterol for certain patients.

Lp(a). Lipoprotein(a) is a genetically determined cholesterol particle that significantly elevates cardiovascular risk and responds poorly to lifestyle changes or standard statin therapy. Most Americans have never had it tested. It doesn't appear on a standard lipid panel.

Inflammatory markers. C-reactive protein (CRP), particularly high-sensitivity CRP, reflects arterial inflammation — a key driver of plaque progression that cholesterol numbers alone don't capture.

Context. A 55-year-old with a family history of early heart disease, high blood pressure, and borderline LDL is in a very different situation than a 35-year-old with the same LDL and no other risk factors. Risk calculators that incorporate multiple variables have largely replaced single-number thresholds in clinical guidelines.

Why the Old Labels Persisted

Simplicity has real value in public health communication. A message that patients remember and act on — even if imperfect — can outperform a technically accurate message that nobody retains. The good/bad cholesterol framework drove real behavior change: people reduced saturated fat intake, started exercising, and took medication adherence seriously.

The issue is that the simplified message also created blind spots. People with "good" cholesterol numbers sometimes developed serious heart disease. People with "bad" numbers sometimes had minimal actual risk. The framework didn't account for those gaps, and patients often weren't told the nuance existed.

The Takeaway

Your cholesterol numbers are worth knowing — they're just worth knowing in context. If you have a history of heart disease, diabetes, or significant family risk, it may be worth asking your doctor about ApoB, Lp(a), or a more comprehensive lipid assessment beyond the standard panel. The science has moved significantly in the last 20 years. The patient handout, in many cases, hasn't quite caught up.